CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial.

@article{Feagan2006CDP571AH,
  title={CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial.},
  author={Brian G Feagan and W J Sandborn and Gabriela Lichtenstein and Graham Radford-Smith and Jatin B. Patel and Alison J Innes},
  journal={Alimentary pharmacology & therapeutics},
  year={2006},
  volume={23 5},
  pages={617-28}
}
BACKGROUND More than 50% of patients with Crohn's disease become either steroid resistant or dependent. Accordingly, development of new treatments for steroid-dependent Crohn's disease is a research priority. AIM To evaluate CDP571, a humanized antibody to tumour necrosis factor-alpha, for the treatment of steroid-dependent Crohn's disease. METHODS… CONTINUE READING